The metabolic syndrome in primary aldosteronism
- First Online:
- 58 Downloads
Patients with hypertension have a high prevalence of concurrent metabolic abnormalities (eg, obesity, dyslipidemia, and hyperglycemia). Clustering of these risk factors, defined as the metabolic syndrome, is associated with a high cardiovascular risk profile. This review summarizes current knowledge about the prevalence and characteristics of the metabolic syndrome in primary aldosteronism, and discusses the possible pathophysiological link between aldosterone and individual components of the metabolic syndrome, other than hypertension. Impaired glucose metabolism due to insulin resistance appears to be the major contributor to metabolic dysfunction in primary aldosteronism. Experimental observations support the possibility that aldosterone could act directly on insulin receptor function. The potential proadipogenic role of aldosterone and its negative effect on insulin sensitivity through production of cytokines remains to be investigated. Higher rates of cardiovascular events reported in primary aldosteronism could be due in part to the increased prevalence of the metabolic syndrome in this disorder.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 4.Reaven GM: Syndrome X: 6 years later. J Intern Med 1994 736(Suppl):13–22.Google Scholar
- 7.Grundy SM, Cleeman JI, Daniels SR, et al., for the American Heart Association and National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.PubMedCrossRefGoogle Scholar
- 8.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar
- 12.Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S5–S20Google Scholar
- 18.Caprio M, Claes A, Viengchareun S, et al.: Aldosterone promotes differentiation in 3T3-L1 cells through specific activation of the mineralocorticoid receptor [abstract]. 87th Annual Meeting of the Endocrine Society. San Diego, CA: June 4–7, 2005. Abstract P2-268.Google Scholar
- 32.Lamouniere-Zepter V, Ehrhart-Bornstein M: Fat tissue and adrenal steroid secretion. Curr Hypertens Rep 2006, 8:30–34.Google Scholar
- 35.Shamiss A, Carroll J, Rosenthal T: Insulin resistance in secondary hypertension. Am J Hypertens 1992, 10:755–759.Google Scholar
- 37.Ishimori M, Takeda N, Okumura S, et al.: Increased insulin sensitivity in patients with aldosterone producing adenoma. Clin Endocrinol 1994, 41:433–438.Google Scholar